CAJ | 학술논문

目的分析晚期胃癌患者DCF和XELOX化疗方案的疗效和安全性,探讨晚期胃癌治疗适宜的化疗方案.方法 63例晚期胃癌化疗患者,分为A组(DCF方案)31例:多西紫杉醇60～ 75 mg/m2第1天；氟尿嘧啶500 mg/m2第1天至第5天,顺铂75 mg/m2,第1天,21 d为1个周期.B组(XELOX方案)32例:奥沙利铂130 mg/m2第1天；卡培他滨1000 mg/m2,2次/d口服,第1天至第14天.结果 63例均可评价不良反应及客观疗效.A、B两组有效率(完全缓解+部分缓解)分别为58.1％和62.5％；中位生存期分别为10.9个月和11.5个月,两组比较差异均无统计学意义(P＞0.05)；两组不良反应均可耐受,A组骨髓抑制3级以上发生率(16.1％)比B组(9.3％)稍高；2～3级以上脱发发生率(77.4％)比B组(0)高.B组手足综合征毒性发生率(68.8％)高于A组(9.6％),肝损伤发生率(37.5％)比A组(16.1％)高,但多为轻度.结论 DCF、XELOX方案治疗晚期胃癌疗效相当,不良反应均可耐受.
목적 분석만기위암환자DCF화XELOX화료방안적료효화안전성,탐토만기위암치료괄의적화료방안.방법 63례만기위암화료환자,분위A조(DCF방안)31례:다서자삼순60～ 75 mg/m2제1천；불뇨밀정500 mg/m2제1천지제5천,순박75 mg/m2,제1천,21 d위1개주기.B조(XELOX방안)32례:오사리박130 mg/m2제1천；잡배타빈1000 mg/m2,2차/d구복,제1천지제14천.결과 63례균가평개불량반응급객관료효.A、B량조유효솔(완전완해+부분완해)분별위58.1％화62.5％；중위생존기분별위10.9개월화11.5개월,량조비교차이균무통계학의의(P＞0.05)；량조불량반응균가내수,A조골수억제3급이상발생솔(16.1％)비B조(9.3％)초고；2～3급이상탈발발생솔(77.4％)비B조(0)고.B조수족종합정독성발생솔(68.8％)고우A조(9.6％),간손상발생솔(37.5％)비A조(16.1％)고,단다위경도.결론 DCF、XELOX방안치료만기위암료효상당,불량반응균가내수.
Objective To analyze the efficacy and safety of DCF and XELOX regimens in the treatment of advanced gastric cancer and to explore the appropriate chemotherapy regimen for advanced gastric cancer.Methods 63 patients with advanced gastric cancer were divided into two groups.Group A (31 patients) was administered with DCF regimen,with docetaxel 60-75 mg/m2 on day 1,5-fluorouracil 500 mg/m2 on day 1 to day 5,cisplatin 75 mg/m2 on day 1,a total cycle of 21 days.Group B (32 patients) was performed with XELOX regimen,with oxaliplatin 130 mg/m2 on day 1,capecitabine 100 mg/m2 twice a day on day 1 to day 14.Results 63 cases were eligible to analyze the efficacy and adverse reactions.The efficient rate (PR+CR) of group A and B were 58.1％ and 62.5 ％,respectively.The median survival time were 10.9 months and 11.5 months,but there were no significant difference between the two groups (P ＞ 0.05).The patients in both groups showed the similar tolerance of adverse reaction.Bone marrow suppression above level 3 in group A (16.1％) was higher than that in group B (9.3 ％).Hair loss above level 2-3 in group A was higher (77.4 ％).Hand-foot syndrome in group B (68.8 ％) was higher than that in group A (9.6 ％).Mild liver function damage in group B (37.5 ％) was higher than that in group A (16.1％).Conclusion The DCF and XELOX schemes have the similar effect in the treatment of advanced gastric cancer with the tolerate side effect.